Laetitia Bigger, Director, Vaccines Policy at IFPMA, spoke with Jenny Sia, Director of Corporate Responsibility at the Pfizer Foundation, about innovations in mHealth technology that are helping to increase access to vaccines. Jenny leads global health grant making and impact investing for the Pfizer Foundation, a charitable organization aiming to promote access to quality health...
Read moreSince the start of the 21st century, Gavi, the Vaccine Alliance, has transformed lives, preventing more than 10 million potential deaths. In 2002, when AIDS, TB and malaria appeared unstoppable, the Global Fund to fight these three fatal diseases was created and since then has saved millions of lives – 27 million as of 2017....
Read moreDelivered by Vanessa Peberdy, Manager, Global Health Policy, IFPMA IFPMA strongly welcomes the upcoming first-ever United Nations high-level meeting (UNHLM) on Universal Health Coverage (UHC). We also support the WHO’s ambitious goal to ensure a billion more people benefit from UHC – as outlined in GPW 13 – and welcome the recognition that UHC must...
Read moreSubstandard and falsified medical products are two different threats to patient’s health that can result in death, disability, and increased illness for patients. Their broader implications in healthcare however, go far beyond: from adding to the problem of antimicrobial resistance to creating mistrust in health systems and healthcare professionals, these products represent added costs to...
Read morePandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits Delivered by Paula Barbosa, Manager, Vaccines Policy Pandemic influenza is a top global health priority for WHO in 2019. Seasonal influenza is also a significant public health concern, and the associated infrastructure required to support seasonal programs also enhances pandemic preparedness. The timely development and production of...
Read moreDelivered by Vanessa Peberdy, Manager, Global Health Policy, IFPMA IFPMA welcomes the Political Declaration of the third High Level Meeting on NCDs, held in September last year. We were encouraged by the high political attention given to the meeting and the adoption of 14 new commitments by Heads of States and Government, as well as...
Read moreThis oped was first published on The Nation on 30 January 2019. It’s clear we live in a global village when England striker Jamie Vardy of Thai-owned Leicester City[1] praises Thai rocker Toon Bodyslam’s 2,215 km charity run over 55 days in 2017 that raised Bt1.37 billion/$35 million for 11 public hospitals and says: “Your actions...
Read moreDelivered by Sara Amini, Senior Manager, Social and Economic Policy, IFPMA IFPMA and its members are fully committed to partnering with governments and the WHO to improve access to and affordability of treatments to fight cancer. We are concerned that the Technical Report has been developed without adequate consultations with key stakeholders, including industry, as...
Read moreDelivered by Grega Kumer, Head of DG Office & Legal Issues, IFPMA The access roadmap offers an opportunity for WHO to address immediate patient needs worldwide. We welcome that WHO has put emphasis on areas where it has a unique mandate and that are covered by the Thirteenth GPW, such as those under “ensuring the...
Read more“This blog was first published in Pharma Exec on 23 January 2019″ As a Brit living and working abroad, I am transfixed by what I’m witnessing together with many others, as the fallout from the June 2016 referendum continues to wrack the UK political landscape. As scenarios, timelines, policy implications (including for the pharmaceutical...
Read moreGeneva, 23 January 2019: IFPMA, the global R&D biopharmaceutical industry association, welcomes the 11th G-FINDER report[i] which tracks public, private and philanthropic investment into product R&D for neglected diseases, which predominantly affect the developing countries. As with previous years, the report shows Bio-pharmaceutical industry investment as the third largest funder, after the USA’s National Institutes...
Read moreThis oped was published first on IP Watch on 16 January 2019 The views expressed in this article are solely those of the authors and are not associated with Intellectual Property Watch. IP-Watch expressly disclaims and refuses any responsibility or liability for the content, style or form of any posts made to this forum, which...
Read more